Reducing Colorectal Cancer Mortality with CF10
Abstract
Purpose: The purpose of this project is to test a novel 2nd generation fluoropyrimidine (FP) polymer, CF10, for improved treatment of colon cancer with an emphasis on liver metastases, a primary cause of cancer mortality impacting mission readiness and the civilian population. Scope: Studies test CF10 and CF10 in combination with oxaliplatin in the WAG/Rij rat model of liver metastases, in primary colon cancer models including patient derived organoids and patient derived xenografts, and in a syngeneic orthotopic colon cancer model for induction of immunogenic cell death and efficacy in combination with immune checkpoint blockade therapy Major Findings: CF10 is well tolerated in rats and mice and displayed promising activity towards liver metastases in a pilot study in the WAG/Rij rat model. Strong activity much greater than 5-FU, is detected in primary colon cancer models. CF10 induced calreticulin translocation to the plasma membrane of cancer cells consistent with inducing immunogenic cell death.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2022
- Accession Number
- AD1192596
Entities
People
- William H. Gmeiner
Organizations
- Wake Forest University